T. Rowe Price Associates, Inc. 13D and 13G filings for MoonLake Immunotherapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-14 10:45 am Sale | 2025-03-31 | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | T. Rowe Price Associates, Inc. | 2,974,271 4.700% | -369,372 (-11.05%) | Filing |
| 2025-02-14 09:44 am Purchase | 2024-12-31 | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | T. Rowe Price Associates, Inc. | 3,343,643 5.300% | 2,521,042 (+306.47%) | Filing |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | T. Rowe Price Associates, Inc. | 822,601 2.100% | 75,739 (+10.14%) | Filing |